Penumbra, Inc. (NYSE:PEN – Get Rating) CEO Adam Elsesser sold 9,666 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $324.49, for a total value of $3,136,520.34. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Adam Elsesser also recently made the following trade(s):
- On Thursday, May 11th, Adam Elsesser sold 9,666 shares of Penumbra stock. The shares were sold at an average price of $318.52, for a total transaction of $3,078,814.32.
Penumbra Stock Performance
Penumbra stock opened at $338.28 on Friday. The firm’s 50-day simple moving average is $302.86 and its 200-day simple moving average is $265.66. The company has a market cap of $12.94 billion, a P/E ratio of 2,114.38 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.37 and a quick ratio of 3.02. Penumbra, Inc. has a fifty-two week low of $114.86 and a fifty-two week high of $342.68.
Penumbra (NYSE:PEN – Get Rating) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.12. Penumbra had a net margin of 0.73% and a return on equity of 1.58%. The firm had revenue of $241.40 million during the quarter, compared to analyst estimates of $229.70 million. During the same quarter last year, the business posted ($0.01) EPS. The company’s revenue was up 18.4% on a year-over-year basis. As a group, equity research analysts predict that Penumbra, Inc. will post 1.56 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of PEN. Raymond James & Associates raised its position in Penumbra by 8.1% during the first quarter. Raymond James & Associates now owns 8,565 shares of the company’s stock valued at $1,903,000 after buying an additional 641 shares during the period. Citigroup Inc. boosted its holdings in shares of Penumbra by 44.5% during the first quarter. Citigroup Inc. now owns 4,979 shares of the company’s stock worth $1,106,000 after purchasing an additional 1,534 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Penumbra by 15.7% during the first quarter. PNC Financial Services Group Inc. now owns 1,211 shares of the company’s stock worth $269,000 after purchasing an additional 164 shares during the period. Great West Life Assurance Co. Can boosted its holdings in shares of Penumbra by 8.0% during the first quarter. Great West Life Assurance Co. Can now owns 19,045 shares of the company’s stock worth $4,348,000 after purchasing an additional 1,417 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Penumbra by 3.1% during the first quarter. Dimensional Fund Advisors LP now owns 90,610 shares of the company’s stock worth $20,123,000 after purchasing an additional 2,717 shares during the period. 82.42% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equity analysts have commented on PEN shares. Royal Bank of Canada raised their target price on shares of Penumbra from $289.00 to $303.00 in a research note on Wednesday, May 3rd. 92 Resources reaffirmed a “maintains” rating on shares of Penumbra in a research note on Wednesday, May 24th. Canaccord Genuity Group increased their price target on Penumbra from $246.00 to $286.00 and gave the company a “buy” rating in a research note on Friday, February 24th. Needham & Company LLC downgraded Penumbra from a “buy” rating to a “hold” rating in a research note on Wednesday, March 29th. Finally, Citigroup boosted their price objective on Penumbra from $303.00 to $325.00 and gave the stock a “buy” rating in a research note on Monday, April 3rd. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $297.67.
Penumbra Company Profile
(Get Rating)
Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.
See Also
Receive News & Ratings for Penumbra Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Penumbra and related companies with MarketBeat.com’s FREE daily email newsletter.